Initiation of Opioid Prescription and Risk of Suicidal Behavior Among Youth and Young Adults

• Published in: Pediatrics (Evanston) 2022-03, Vol.149 (3), p.11-11
• Main Authors: Fine, Kimberly L, Rickert, Martin E, O'Reilly, Lauren M, Sujan, Ayesha C, Boersma, Katja, Chang, Zheng, Franck, Johan, Lichtenstein, Paul, Larsson, Henrik, D'Onofrio, Brian M, Quinn, Patrick D
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Analgesics; Analgesics, Opioid - adverse effects; Anesthesiology/Pain Medicine; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Child; Health aspects; Humans; Medicin och hälsovetenskap; Narcotics; Nonsteroidal anti-inflammatory drugs; Opioids; Pain - drug therapy; Pediatrics; Prescriptions; Psychiatry/Psychology; Psychological aspects; Risk factors; Self-injury; Sensitivity analysis; Suicidal behavior; Suicidal behaviour; Suicidal Ideation; Suicide; Suicides & suicide attempts; Teenagers; Young Adult; Young adults; Youth
• ISSN: 0031-4005; 1098-4275; 1098-4275
• DOI: 10.1542/peds.2020-049750

Opioids are involved in an increasing proportion of suicide deaths. This study examined the association between opioid analgesic prescription initiation and suicidal behavior among young people. We analyzed Swedish population-register data on 1 895 984 individuals ages 9 to 29 years without prior recorded opioid prescriptions. We identified prescriptions dispensed from January 2007 onward and diagnosed self-injurious behavior and death by suicide through December 2013. We first compared initiators with demographically matched noninitiators. To account for confounding, we applied an active comparator design, which examined suicidal behavior among opioid initiators relative to prescription nonsteroidal antiinflammatory drug (NSAID) initiators while inverse-probability-of-treatment weighting with individual and familial covariates. Among the cohort, 201 433 individuals initiated opioid prescription. Relative to demographically matched noninitiators, initiators (N = 180 808) had more than doubled risk of incident suicidal behavior (hazard ratio = 2.64; 95% confidence interval [CI], 2.47-2.81). However, in the active comparator design, opioid initiators (N = 86 635) had only 19% relatively greater risk of suicidal behavior compared with NSAID initiators (N = 255 096; hazard ratio = 1.19; 95% CI,: 1.11-1.28), corresponding to a weighted 5-year cumulative incidence of 2.2% (95% CI, 2.1-2.4) for opioid and 1.9% (95% CI, 1.9-2.0) for NSAID initiators. Most sensitivity analyses produced comparable results. Opioid initiation may make only a small contribution to the elevated risk of suicidal behavior among young people receiving pharmacologic pain management. In weighing benefits and harms of opioid initiation, our results suggest that increased risk of suicidal behavior may not be a major concern.